Lyell Current Ratio from 2010 to 2025

LYEL Stock  USD 0.56  0.02  3.59%   
Lyell Immunopharma Current Ratio yearly trend continues to be quite stable with very little volatility. The value of Current Ratio is projected to decrease to 6.70. Current Ratio is a liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities. View All Fundamentals
 
Current Ratio  
First Reported
2010-12-31
Previous Quarter
7.05722466
Current Value
6.7
Quarterly Volatility
4.67116957
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lyell Immunopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lyell Immunopharma's main balance sheet or income statement drivers, such as Net Interest Income of 12.8 M, Interest Income of 12.8 M or Depreciation And Amortization of 13.9 M, as well as many indicators such as Price To Sales Ratio of 2.5 K, Dividend Yield of 0.0 or PTB Ratio of 0.42. Lyell financial statements analysis is a perfect complement when working with Lyell Immunopharma Valuation or Volatility modules.
  
Check out the analysis of Lyell Immunopharma Correlation against competitors.
For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.

Latest Lyell Immunopharma's Current Ratio Growth Pattern

Below is the plot of the Current Ratio of Lyell Immunopharma over the last few years. It is a liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities. Lyell Immunopharma's Current Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lyell Immunopharma's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 13.26 X10 Years Trend
Slightly volatile
   Current Ratio   
       Timeline  

Lyell Current Ratio Regression Statistics

Arithmetic Mean17.07
Geometric Mean16.21
Coefficient Of Variation27.37
Mean Deviation3.70
Median19.97
Standard Deviation4.67
Sample Variance21.82
Range13.2709
R-Value(0.77)
Mean Square Error9.48
R-Squared0.59
Significance0.0005
Slope(0.76)
Total Sum of Squares327.30

Lyell Current Ratio History

2025 6.7
2024 7.06
2023 16.07
2022 17.59
2021 13.4
2020 12.53

About Lyell Immunopharma Financial Statements

Lyell Immunopharma investors utilize fundamental indicators, such as Current Ratio, to predict how Lyell Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Ratio 7.06  6.70 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Lyell Immunopharma is a strong investment it is important to analyze Lyell Immunopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lyell Immunopharma's future performance. For an informed investment choice regarding Lyell Stock, refer to the following important reports:
Check out the analysis of Lyell Immunopharma Correlation against competitors.
For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.31)
Quarterly Revenue Growth
(0.15)
Return On Assets
(0.22)
Return On Equity
(0.66)
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.